Itulazax

Betula verrucosa, the active ingredient in Itulazax, is an allergen extract presented as a sublingual preparation for sublingual use. It is indicated for the treatment of allergic rhinitis caused by birch pollen in individuals with IgE‑mediated sensitivity.

GNH USA supplies Itulazax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company ensures quality compliance with EU standards and provides reliable distribution to healthcare providers across multiple regions.

Itulazax is used in allergen immunotherapy to address birch‑pollen‑induced allergic rhinitis.

- Allergic rhinitis (birch pollen): reduces nasal congestion, sneezing and itching. - Seasonal allergic rhinitis (birch): improves tolerance and decreases medication reliance. - IgE‑mediated birch pollen allergy: induces long‑term immunologic tolerance.

Sublingual exposure to Betula verrucosa extract may cause local and systemic reactions.

Common Side Effects: - Oral itching or mild burning sensation. - Throat irritation or mild soreness. - Slight swelling of the lips or tongue. - Transient nasal congestion. - Mild headache. - Temporary increase in sneezing.

Serious or Rare Side Effects: - Anaphylaxis or severe systemic allergic reaction. - Angioedema involving the face, lips or airway. - Severe bronchospasm or respiratory distress.

Before initiating therapy, clinicians should evaluate patient suitability and monitor for reactions.

- Allergy assessment: confirm IgE‑mediated birch pollen sensitivity. - Asthma control: avoid use in patients with uncontrolled asthma. - Local reaction monitoring: observe for persistent oral or throat irritation. - Systemic reaction protocol: discontinue and seek emergency care if systemic symptoms develop. - Concomitant immunotherapy: avoid simultaneous use of other allergen extracts without specialist guidance. - Store at room temperature: keep in the original packaging, protect from moisture and direct sunlight.

Betula verrucosa extract may interact with certain medications that affect immune or allergic responses.

Major Interactions (Avoid): - Beta‑blockers: may mask signs of anaphylaxis and complicate emergency treatment. - ACE inhibitors: increase risk of angioedema during systemic reactions.

Moderate Interactions (Monitor Closely): - Immunosuppressants (e.g., corticosteroids, methotrexate): may reduce efficacy of immunotherapy. - Antihistamines: may blunt local reaction signs, requiring careful monitoring. - NSAIDs: can exacerbate gastrointestinal irritation when combined with oral extracts.